Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Phathom Pharmaceuticals (PHAT) Other Gross PP&E Adjustments (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Other Gross PP&E Adjustments for 5 consecutive years, with -$3.5 million as the latest value for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments fell 245.52% year-over-year to -$3.5 million; the TTM value through Mar 2026 reached -$3.5 million, down 245.52%, while the annual FY2025 figure was $683000.0, 72.69% down from the prior year.
  • Other Gross PP&E Adjustments hit -$3.5 million in Q1 2026 for Phathom Pharmaceuticals, down from $683000.0 in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $2.5 million in Q4 2024 and bottomed at -$4.8 million in Q2 2022.
  • Average Other Gross PP&E Adjustments over 5 years is -$920235.3, with a median of -$1.0 million recorded in 2025.
  • Year-over-year, Other Gross PP&E Adjustments skyrocketed 396.08% in 2024 and then plummeted 247.23% in 2025.
  • Phathom Pharmaceuticals' Other Gross PP&E Adjustments stood at -$2.6 million in 2022, then soared by 136.26% to $946000.0 in 2023, then skyrocketed by 164.38% to $2.5 million in 2024, then tumbled by 72.69% to $683000.0 in 2025, then plummeted by 613.47% to -$3.5 million in 2026.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$3.5 million, $683000.0, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.